APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nasal Flu Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nasal Flu Vaccine Market Outlook and Growth Opportunities 2026

2 January 2026195 pages

Choose your research edition.

Industry ResearchNasal Flu Vaccine Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Nasal Flu Vaccine Industry Growth and Trends Forecast to 203276 pages · $3,450 USDMarket StructureGlobal Nasal Flu Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032170 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nasal Flu Vaccine Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Nasal Flu Vaccine Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Nasal Flu Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nasal Flu Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nasal Flu Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nasal Flu Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nasal Flu Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nasal Flu Vaccine market include AstraZeneca and Beike Bio among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Nasal Flu Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nasal Flu Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nasal Flu Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Nasal Flu Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Nasal Flu Vaccine Segment by Company

AstraZeneca

Beike Bio

Nasal Flu Vaccine Segment by Type

Trivalent Flu Vaccine

Quadrivalent Flu Vaccine

Nasal Flu Vaccine Segment by Application

Child

Adult

Nasal Flu Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Nasal Flu Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Nasal Flu Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nasal Flu Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Nasal Flu Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nasal Flu Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nasal Flu Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nasal Flu Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Nasal Flu Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nasal Flu Vaccine industry.

Chapter 3: Detailed analysis of Nasal Flu Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Nasal Flu Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Nasal Flu Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nasal Flu Vaccine Industry Trends Table 2. Nasal Flu Vaccine Industry Drivers Table 3. Nasal Flu Vaccine Industry Opportunities and Challenges Table 4. Nasal Flu Vaccine Industry Restraints Table 5. Global Nasal Flu Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nasal Flu Vaccine Revenue Share by Company (2021-2026) Table 7. Global Nasal Flu Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Nasal Flu Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Nasal Flu Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Nasal Flu Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Nasal Flu Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Nasal Flu Vaccine Company, Product Type & Application Table 13. Global Nasal Flu Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Nasal Flu Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Trivalent Flu Vaccine Table 18. Significant Companies of Quadrivalent Flu Vaccine Table 19. Global Nasal Flu Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Nasal Flu Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Nasal Flu Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Nasal Flu Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Nasal Flu Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Nasal Flu Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Nasal Flu Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Nasal Flu Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Nasal Flu Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Nasal Flu Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Child Table 30. Significant Companies of Adult Table 31. Global Nasal Flu Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Nasal Flu Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Nasal Flu Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Nasal Flu Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Nasal Flu Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Nasal Flu Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Nasal Flu Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Nasal Flu Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Nasal Flu Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Nasal Flu Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Nasal Flu Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Nasal Flu Vaccine Sales by Region (2021-2026) & (K Units) Table 43. Global Nasal Flu Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Nasal Flu Vaccine Sales by Region (2027-2032) & (K Units) Table 45. Global Nasal Flu Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Nasal Flu Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Nasal Flu Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Nasal Flu Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Nasal Flu Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Nasal Flu Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Nasal Flu Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Nasal Flu Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Nasal Flu Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Nasal Flu Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Nasal Flu Vaccine Sales by Country (2021-2026) & (K Units) Table 56. Global Nasal Flu Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Nasal Flu Vaccine Sales by Country (2027-2032) & (K Units) Table 58. Global Nasal Flu Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Nasal Flu Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Nasal Flu Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Nasal Flu Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Nasal Flu Vaccine Sales Value Market Share by Country (2027-2032) Table 63. AstraZeneca Company Information Table 64. AstraZeneca Business Overview Table 65. AstraZeneca Nasal Flu Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. AstraZeneca Nasal Flu Vaccine Product Portfolio Table 67. AstraZeneca Recent Development Table 68. Beike Bio Company Information Table 69. Beike Bio Business Overview Table 70. Beike Bio Nasal Flu Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Beike Bio Nasal Flu Vaccine Product Portfolio Table 72. Beike Bio Recent Development Table 73. Key Raw Materials Table 74. Raw Materials Key Suppliers Table 75. Nasal Flu Vaccine Distributors List Table 76. Nasal Flu Vaccine Customers List Table 77. Research Programs/Design for This Report Table 78. Authors List of This Report Table 79. Secondary Sources Table 80. Primary Sources List of Figures Figure 1. Nasal Flu Vaccine Product Image Figure 2. Global Nasal Flu Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nasal Flu Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Nasal Flu Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Nasal Flu Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Nasal Flu Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Trivalent Flu Vaccine Image Figure 10. Quadrivalent Flu Vaccine Image Figure 11. Global Nasal Flu Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Nasal Flu Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Nasal Flu Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Nasal Flu Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Nasal Flu Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Nasal Flu Vaccine Sales Value Share by Type (2021-2032) Figure 17. Child Image Figure 18. Adult Image Figure 19. Global Nasal Flu Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Nasal Flu Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Nasal Flu Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Nasal Flu Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Nasal Flu Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Nasal Flu Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Nasal Flu Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Nasal Flu Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Nasal Flu Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Nasal Flu Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Nasal Flu Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Nasal Flu Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Nasal Flu Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Nasal Flu Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Nasal Flu Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Nasal Flu Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Nasal Flu Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Nasal Flu Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Nasal Flu Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Nasal Flu Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Nasal Flu Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Nasal Flu Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Nasal Flu Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Trivalent Flu Vaccine
  • Quadrivalent Flu Vaccine
Applications
  • Child
  • Adult
Companies covered
  • AstraZeneca
  • Beike Bio

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Nasal Flu Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Nasal Flu Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Nasal Flu Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Nasal Flu Vaccine Market Dynamics
  1. 2.1 Nasal Flu Vaccine Industry Trends
  2. 2.2 Nasal Flu Vaccine Industry Drivers
  3. 2.3 Nasal Flu Vaccine Industry Opportunities and Challenges
  4. 2.4 Nasal Flu Vaccine Industry Restraints
3 Nasal Flu Vaccine Market by Company
  1. 3.1 Global Nasal Flu Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Nasal Flu Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Nasal Flu Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Nasal Flu Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Nasal Flu Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Nasal Flu Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Nasal Flu Vaccine Company Product Type and Application
  8. 3.8 Global Nasal Flu Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Nasal Flu Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Nasal Flu Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Nasal Flu Vaccine Market by Type
  1. 4.1 Nasal Flu Vaccine Type Introduction
  2. 4.1.1 Trivalent Flu Vaccine
  3. 4.1.2 Quadrivalent Flu Vaccine
  4. 4.2 Global Nasal Flu Vaccine Sales Volume by Type
  5. 4.2.1 Global Nasal Flu Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Nasal Flu Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Nasal Flu Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Nasal Flu Vaccine Sales Value by Type
  9. 4.3.1 Global Nasal Flu Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Nasal Flu Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Nasal Flu Vaccine Sales Value Share by Type (2021-2032)
5 Nasal Flu Vaccine Market by Application
  1. 5.1 Nasal Flu Vaccine Application Introduction
  2. 5.1.1 Child
  3. 5.1.2 Adult
  4. 5.2 Global Nasal Flu Vaccine Sales Volume by Application
  5. 5.2.1 Global Nasal Flu Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Nasal Flu Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Nasal Flu Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Nasal Flu Vaccine Sales Value by Application
  9. 5.3.1 Global Nasal Flu Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Nasal Flu Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Nasal Flu Vaccine Sales Value Share by Application (2021-2032)
6 Nasal Flu Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Nasal Flu Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nasal Flu Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Nasal Flu Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Nasal Flu Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Nasal Flu Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Nasal Flu Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Nasal Flu Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Nasal Flu Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Nasal Flu Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Nasal Flu Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Nasal Flu Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Nasal Flu Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Nasal Flu Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Nasal Flu Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Nasal Flu Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Nasal Flu Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Nasal Flu Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Nasal Flu Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Nasal Flu Vaccine Sales Value Share by Country, 2025 VS 2032
7 Nasal Flu Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Nasal Flu Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nasal Flu Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Nasal Flu Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Nasal Flu Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Nasal Flu Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Nasal Flu Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Nasal Flu Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Nasal Flu Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Nasal Flu Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Nasal Flu Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Nasal Flu Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AstraZeneca
  2. 8.1.1 AstraZeneca Company Information
  3. 8.1.2 AstraZeneca Business Overview
  4. 8.1.3 AstraZeneca Nasal Flu Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AstraZeneca Nasal Flu Vaccine Product Portfolio
  6. 8.1.5 AstraZeneca Recent Developments
  7. 8.2 Beike Bio
  8. 8.2.1 Beike Bio Company Information
  9. 8.2.2 Beike Bio Business Overview
  10. 8.2.3 Beike Bio Nasal Flu Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Beike Bio Nasal Flu Vaccine Product Portfolio
  12. 8.2.5 Beike Bio Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Nasal Flu Vaccine Value Chain Analysis
  2. 9.1.1 Nasal Flu Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Nasal Flu Vaccine Sales Mode & Process
  6. 9.2 Nasal Flu Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Nasal Flu Vaccine Distributors
  9. 9.2.3 Nasal Flu Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst